Tripartite motif-containing 29 (TRIM29), also known as ataxia-telangiectasia group D, is structurally a member of the tripartite motif family of proteins, which characterized by the conserved RING finger, B-box, and coiled-coil domains. TRIM29 functions as an oncogene or a tumor suppressor depending on the tumor types. In this study, we aim to evaluate whether TRIM29 affects the tumorigenesis and progression of colorectal cancer. The expression of TRIM29 was investigated using real-time PCR in 40 pairs of colorectal cancer tissues and immunohistochemistry on a tissue microarray containing 203 cases of primary colorectal cancer paired with non-cancerous tissues. Down-regulation of TRIM29 was achieved by transient transfection in RKO cell lines, and the effects of TRIM29 on tumor proliferation were evaluated by MTT and plate colony formation assays. Results indicated that TRIM29 expression was much higher in colorectal cancer tissues and significantly associated with the depth of tumor invasion, lymph node metastasis, distant metastasis, histological differentiation, vascular invasion, ki-67 index, and advanced tumor stage. Patients with TRIM29-positive tumors had a higher recurrence rate and poorer survival than patients with TRIM29-negative tumors. In multivariate analyses, the TRIM29 expression was an independent factor for determining colorectal cancer prognosis after surgery. Moreover, down-regulation of TRIM29 inhibited tumor cell proliferation in vitro. In conclusion, TRIM29 plays an important role in promoting colorectal cancer progression. Our findings suggest that TRIM29 may serve as a novel biomarker for tumor recurrence and survival for colorectal cancer patients.
Tripartite motif-containing 29 Colorectal cancer Prognosis Immunohistochemistry
This is a preview of subscription content, log in to check access.
The project was supported by the grants from National Natural Science Foundation of China (81072008, 81172328) and Medical engineering crossing project grant funded by Shanghai Jiaotong University (YG2011MS59).
Gaedcke J, et al. The rectal cancer microRNAome–microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 2012;18(18):4919–30.CrossRefPubMedGoogle Scholar
Siegel R, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.CrossRefPubMedGoogle Scholar
Zhang S, et al. Changes on the disease pattern of primary colorectal cancers in Southern China: a retrospective study of 20 years. Int J Colorectal Dis. 2009;24(8):943–9.CrossRefPubMedGoogle Scholar
Schepeler T, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008;68(15):6416–24.CrossRefPubMedGoogle Scholar
Compton CC, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):979–94.PubMedGoogle Scholar
Nakamura Y, et al. Case of the multiple liver metastases from colon cancer obtained long-term disease-free survival with multimodality therapy. Gan To Kagaku Ryoho. 2012;39(12):2228–30.PubMedGoogle Scholar
Kosaka Y, et al. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol. 2007;14(9):2543–9.CrossRefPubMedGoogle Scholar
Mutter GL, et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol. 2001;83(2):177–85.CrossRefPubMedGoogle Scholar
Santin AD, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112(1):14–25.CrossRefPubMedGoogle Scholar
Dyrskjot L, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004;64(11):4040–8.CrossRefPubMedGoogle Scholar
Hawthorn L, et al. Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. Lung Cancer. 2006;53(2):129–42.CrossRefPubMedGoogle Scholar
Li D, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009;16(12):3499–506.CrossRefPubMedGoogle Scholar
Wang X, et al. Reduced expression of PER3 is associated with incidence and development of colon cancer. Ann Surg Oncol. 2012;19(9):3081–8.CrossRefPubMedGoogle Scholar
Yan DW, et al. Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. Br J Cancer. 2010;103(7):961–9.CrossRefPubMedCentralPubMedGoogle Scholar
Reddy BA, Etkin LD, Freemont PS. A novel zinc finger coiled-coil domain in a family of nuclear proteins. Trends Biochem Sci. 1992;17(9):344–5.CrossRefPubMedGoogle Scholar
Borden KL. RING fingers and B-boxes: zinc-binding protein–protein interaction domains. Biochem Cell Biol. 1998;76(2–3):351–8.CrossRefPubMedGoogle Scholar
Leonhardt EA, et al. Nucleotide sequence analysis of a candidate gene for ataxia-telangiectasia group D (ATDC). Genomics. 1994;19(1):130–6.CrossRefPubMedGoogle Scholar
Brzoska PM, et al. The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor. Proc Natl Acad Sci U S A. 1995;92(17):7824–8.CrossRefPubMedCentralPubMedGoogle Scholar
Lawson JC, Blatch GL, Edkins AL. Cancer stem cells in breast cancer and metastasis. Breast Cancer Res Treat. 2009;118(2):241–54.CrossRefPubMedGoogle Scholar